Effect of Therapeutic Modification on Outcomes in Heart Transplantation Over the Past Two Decades　― A Single-Center Experience in Japan

• Published in: Circulation Journal Vol. 84; no. 6; pp. 965 - 974
• Main Authors: Yanase, Masanobu, Iwasaki, Keiichiro, Watanabe, Takuya, Seguchi, Osamu, Nakajima, Seiko, Kuroda, Kensuke, Mochizuki, Hiroki, Matsuda, Sachi, Takenaka, Hiromi, Ikura, Megumi, Tadokoro, Naoki, Fukushima, Satsuki, Fujita, Tomoyuki, Ishibashi-Ueda, Hatsue, Nakatani, Takeshi, Kitamura, Soichiro, Kobayashi, Junjiro, Tsujita, Kenichi, Ogawa, Hisao, Fukushima, Norihide
• Format: Journal Article
• Language: English
• Published: Japan The Japanese Circulation Society 25.05.2020
• Subjects: Adult; Donor Selection; Everolimus - administration & dosage; Everolimus - adverse effects; Exercise Tolerance; Extracorporeal Circulation; Female; Graft Survival - drug effects; Heart Failure - diagnosis; Heart Failure - physiopathology; Heart Failure - surgery; Heart transplantation; Heart Transplantation - adverse effects; Heart-Assist Devices; Hemodynamics; Humans; Immunosuppression; Immunosuppressive Agents - administration & dosage; Immunosuppressive Agents - adverse effects; Japan; Left ventricular assist device; Male; Marginal donor; Middle Aged; Recovery of Function; Retrospective Studies; Risk Factors; Time Factors; Tissue Donors - supply & distribution; Treatment Outcome; Ventricular Function, Left; Waiting Lists; Japan; Left ventricular assist device; Immunosuppression; Marginal donor; Heart transplantation
• ISSN: 1346-9843; 1347-4820; 1347-4820
• DOI: 10.1253/circj.CJ-19-1209

Background:During these 2 decades (1999–2019), many therapeutic strategies have been developed in the field of heart transplant (HTx) to improve post-HTx outcomes. In the present study, 116 consecutive HTx adults between 1999 and 2019 were retrospectively reviewed to evaluate the influences of a therapeutic modification on post HTx outcomes.Methods and Results:Patient survival, functional status and hemodynamics after HTx and modification of therapeutic strategies were reviewed. The overall cumulative survival rate at 10 and 20 years post-HTx was 96.4 and 76.7%, respectively. There were no significant differences in survival rate or exercise tolerance after HTx between extracorporeal and implantable continuous flow-LVAD. Post-HTx patient survival in patients, irrespective of the donor risk factors such as donor age, low LVEF, history of cardiac arrest, was equivalent across cohorts, while longer TIT and higher inotrope dosage prior to procurement surgery were significant risk factors for survival. In 21 patients given everolimus (EVL) due to renal dysfunction, serum creatinine significantly decreased 1 year after initiation. In 22 patients given EVL due to transplant coronary vasculopathy (TCAV), maximum intimal thickness significantly decreased 3 years after initiation.Conclusions:The analysis of a 20-year single-center experience with HTx in Japan shows encouraging improved results when several therapeutic modifications were made; for example, proactive use of donor hearts declined by other centers and the use of EVL in patients with renal dysfunction and TCAV.